Literature DB >> 19548068

Differential diagnosis and treatment of primary, cutaneous, anaplastic large cell lymphoma: not always an easy task.

Michael D Diamantidis1, Athanasios Papadopoulos2, Georgia Kaiafa2, George Ntaios2, Georgia Karayannopoulou3, Ioannis Kostopoulos3, Fotios Girtovitis2, Zoi Saouli2, Zisis Kontoninas2, Ioannis D Raptis2, Christos Savopoulos2, Apostolos Hatzitolios2.   

Abstract

Primary cutaneous anaplastic large cell lymphoma (PC-ALCL) is a rare and distinct neoplasm appearing de novo on the skin. We present a case of a 75-year-old man diagnosed with PC-ALCL in his left femoral region. We describe the morphology of lesions along with the differential diagnosis, treatment, clinical course and prognosis. We further discuss parameters concerning treatment that should be considered when a PC-ALCL is diagnosed. Our case report demonstrates the complexity in classification, staging, differential diagnosis and therapy selection of PC-ALCLs. It is crucial to emphasize the importance of clinical criteria in diagnosing a PC-ALCL in combination with immunohistochemistry.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19548068     DOI： 10.1007/s12185-009-0365-7

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  10 in total

Review 1.  CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators.

Authors:  Werner Kempf
Journal:  J Cutan Pathol       Date:  2006-02       Impact factor: 1.587

2.  Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment.

Authors:  M W Bekkenk; F A Geelen; P C van Voorst Vader; F Heule; M L Geerts; W A van Vloten; C J Meijer; R Willemze
Journal:  Blood       Date:  2000-06-15       Impact factor: 22.113

Review 3.  Need for an improved molecular/genetic classification for CD30+ lymphomas involving the skin.

Authors:  Claudia Droc; Hernani D Cualing; Marshall E Kadin
Journal:  Cancer Control       Date:  2007-04       Impact factor: 3.302

4.  ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.

Authors:  Kerry J Savage; Nancy Lee Harris; Julie M Vose; Fred Ullrich; Elaine S Jaffe; Joseph M Connors; Lisa Rimsza; Stefano A Pileri; Mukesh Chhanabhai; Randy D Gascoyne; James O Armitage; Dennis D Weisenburger
Journal:  Blood       Date:  2008-04-02       Impact factor: 22.113

5.  Primary cutaneous CD30+ anaplastic large-cell lymphomas mimicking keratoacanthomas.

Authors:  J M Martín; J M Ricart; C Monteagudo; J Alcácer; I Pinazo; L Tomás; N Rausell; E Jordá
Journal:  Clin Exp Dermatol       Date:  2007-11       Impact factor: 3.470

6.  Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma.

Authors:  Katja C Weisel; Eckhart Weidmann; Ioannis Anagnostopoulos; Lothar Kanz; Antonio Pezzutto; Marion Subklewe
Journal:  Int J Hematol       Date:  2008-10-07       Impact factor: 2.490

Review 7.  Anaplastic Large Cell Lymphoma.

Authors:  L Jeffrey Medeiros; Kojo S J Elenitoba-Johnson
Journal:  Am J Clin Pathol       Date:  2007-05       Impact factor: 2.493

8.  Successful treatment for recurrence of primary cutaneous anaplastic large-cell lymphoma in elderly patient with etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone and bleomycin (VNCOP-B) therapy.

Authors:  Rieko Isogai; Makiko Fukao; Akira Kawada
Journal:  J Dermatol       Date:  2007-08       Impact factor: 4.005

9.  Primary cutaneous anaplastic large cell lymphoma with fatal leukemic outcome in association with CLA and CCR4-negative conversion.

Authors:  Yoshiki Tokura; Kazunari Sugita; Hiroaki Yagi; Takatoshi Shimauchi; Kenji Kabashima; Masahiro Takigawa
Journal:  J Am Acad Dermatol       Date:  2007-11       Impact factor: 11.527

Review 10.  Update on extranodal lymphomas. Conclusions of the Workshop held by the EAHP and the SH in Thessaloniki, Greece.

Authors:  E Campo; A Chott; M C Kinney; L Leoncini; C J L M Meijer; C S Papadimitriou; M A Piris; H Stein; S H Swerdlow
Journal:  Histopathology       Date:  2006-04       Impact factor: 5.087
  10 in total
  3 in total

1.  Lymphomatoid papulosis followed by anaplastic large cell lymphoma in a pediatric patient.

Authors:  Jung Ah Min; Shin Taek Oh; Jung Eun Kim; Baik Kee Cho; Nak Gyun Chung; Hyun Jeong Park
Journal:  Ann Dermatol       Date:  2010-11-05       Impact factor: 1.444

Review 2.  EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.

Authors:  Werner Kempf; Katrin Pfaltz; Maarten H Vermeer; Antonio Cozzio; Pablo L Ortiz-Romero; Martine Bagot; Elise Olsen; Youn H Kim; Reinhard Dummer; Nicola Pimpinelli; Sean Whittaker; Emmilia Hodak; Lorenzo Cerroni; Emilio Berti; Steve Horwitz; H Miles Prince; Joan Guitart; Teresa Estrach; José A Sanches; Madeleine Duvic; Annamari Ranki; Brigitte Dreno; Sonja Ostheeren-Michaelis; Robert Knobler; Gary Wood; Rein Willemze
Journal:  Blood       Date:  2011-08-12       Impact factor: 22.113

3.  Primary cutaneous anaplastic large-cell lymphoma--case report.

Authors:  Luciana Silveira Rabello de Oliveira; Madeleyne Palhano Nobrega; Maira Gomes Monteiro; Wagner Leite de Almeida
Journal:  An Bras Dermatol       Date:  2013 Nov-Dec       Impact factor: 1.896
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.